Table 4

Prognostic factors for progression-free survival (PFS) and overall survival (OS) using Cox models

PFSOS
HR95% CIP valueHR95% CIP value
Age, ≥70 years1.020.43 to 2.410.971.700.50 to 5.810.40
ECOG-PS, 1–22.210.77 to 6.380.141.320.34 to 5.050.68
Number of previous regimens, ≥21.110.43 to 2.880.831.340.34 to 5.170.68
Stage, IV or recurrence1.490.60 to 3.690.391.590.47 to 5.450.46
Histology, squamous cell carcinoma1.670.70 to 3.980.251.440.42 to 5.000.56
TPS, <50%1.520.63 to 3.650.350.790.23 to 2.740.71
ΔTLP0−2, ≥60%3.411.34 to 8.650.0102.050.59 to 7.110.26
ΔTLP0−6, ≥50%*31.43.55 to 276.70.00192.140.48 to 9.630.32
  • *N=22. Three patients did not undergo 18F-FLT PET at 6 weeks after treatment initiation because of early disease progression.

  • ECOG-PS, Eastern Cooperative Oncology Group performance status; TLP, total lesion proliferation; TPS, tumor proportion score.